> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alphatec CFO Calls Spine Market A 'Low Single Digit' Grower After Revenue Miss
- URL: https://www.bullished.co/alphatec-cfo-calls-spine-market-a-low-single-digit-grower-after-revenue-miss-163bc2fe/
- Published: 2026-10-29T21:59:15.000Z
- Updated: 2026-10-29T21:59:15.000Z
- Description: CFO Todd Koning would not give 2027 targets and called the second half of 2026 a "pretty good jumping off point" for next year.
- Author: Matteo Parrino
- Tags: Earnings, ATEC, Industry: Healthcare

[Alphatec](https://www.bullished.co/tag/atec/)'s chief financial officer said on the company's earnings call Thursday that the spine market now feels like a "low single digit growing market," down from the mid-single-digit growth the company expected entering the year. Todd Koning also declined to give 2027 guidance after the spine-surgery company reported [$221 million](https://www.businesswire.com/news/home/20261029584488/en/ATEC-Reports-Third-Quarter-Financial-Results?ref=bullished.co) in third-quarter revenue, up 13%.

## A softer market, a lower outlook

Alphatec, based in Carlsbad, California, designs spinal implants, surgical instruments, biologics and an imaging and robotics platform, selling to surgeons through independent agents and direct reps. Koning said slower thoracolumbar procedures among established customers drove the shift, partly offset by strong cervical volume. Total procedure volume still grew 20%.

Koning said the 2026 guide is about $20 million lower year over year: about $4 million in the third quarter and about $16 million in the fourth. Of the fourth-quarter piece, about $12 million is surgical volume and $4 million is EOS, the company's imaging system. In the surgical piece, lower biologics expectations and lower procedure volumes are split roughly evenly.

Chief Executive Pat Miles told a Stifel analyst that volume is slowing among the company's most tenured surgeon customers, and that "it doesn't speak to a competitive dynamic." Biologics, the bone graft products, fell about $1 million from a year earlier, so surgical hardware drove all surgical growth.

## No 2027 guidance, but some markers

A TD Cowen analyst asked about the company's long-range plan of $1 billion in revenue for 2027\. Koning said, "we're not going to get into specific guidance for 2027," citing strong procedural growth and positive signs in EOS capital sales.

On biologics, where the timing and effectiveness of fixes are hard to predict, he said he would "err on the side of caution until we get a little bit more clarity." He called the second half of 2026 "a pretty good jumping off point for how you should think about next year."

Koning suggested a mid-30s percent drop-through of revenue growth to adjusted EBITDA (earnings before interest, taxes, depreciation and amortization). He warned against counting on this year's gross margin, which has benefited from a mix with more hardware and less biologics and EOS.

## The fourth-quarter margin marker

Guidance implies an adjusted EBITDA margin of about 18% in the fourth quarter. Koning said history shows the fourth-quarter exit level is a good indicator of the next year's level.

For 2026, the company now expects revenue of about [$862 million](https://www.businesswire.com/news/home/20261029584488/en/ATEC-Reports-Third-Quarter-Financial-Results?ref=bullished.co), adjusted EBITDA of about $137 million, or 16% of revenue, and free cash flow of $10 million. Koning said formal 2027 guidance will follow the planning process, with fourth-quarter market trends a key variable.

Koning said fourth-quarter market trends will shape how the company frames 2027 when it gives formal guidance.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Alphatec Non-GAAP EPS of $0.09 in-line, revenue of $221M misses by $4.14M (ATEC:NASDAQ)](https://seekingalpha.com/news/4660823-alphatec-non-gaap-eps-of-0%5F09-in-line-revenue-of-221m-misses-by-4%5F14m?ref=bullished.co) — seekingalpha.com
- [Alphatec: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/alphatec-q3-earnings-snapshot-210845067.html?ref=bullished.co) — Associated Press
- [Alphatec: Q3 Earnings Snapshot | king5.com](https://www.king5.com/article/syndication/associatedpress/alphatec-q3-earnings-snapshot/616-cbdbf1c4-bbbc-4da5-9414-0fd2b6ad388c?ref=bullished.co) — Associated Press
- [Alphatec Holdings Inc. v. NuVasive, Inc.](https://www.law360.com/ptab%5Fcases/5c251f5ab2f7fc4d86d50084?ref=bullished.co) — law360.com
- [ATEC Reports Third Quarter Financial Results](https://www.businesswire.com/news/home/20261029584488/en/ATEC-Reports-Third-Quarter-Financial-Results?ref=bullished.co) — businesswire.com

### More on Alphatec Holdings

- [Alphatec Draws Revolver Balance To $70 Million As Cash Drops To $79.9 Million](https://www.bullished.co/alphatec-draws-revolver-balance-to-70-million-as-cash-drops-to-79-9-million-d083283f/)
- [Alphatec Misses Its Own Third-Quarter Plan On Biologics, Cuts Full-Year Revenue Outlook To $862 Million](https://www.bullished.co/alphatec-misses-its-own-third-quarter-plan-on-biologics-cuts-full-year-revenue-outlook-to-d1381456/)

[All Alphatec Holdings (ATEC) coverage →](https://www.bullished.co/tag/atec/)